
                      endocarditis following mitral valve ring annuloplasty by unknown
Parikh and Grant  Ann Clin Microbiol Antimicrob  (2017) 16:14 
DOI 10.1186/s12941-017-0190-4
CASE REPORT
Mycobacterium goodii endocarditis 
following mitral valve ring annuloplasty
Rohan B. Parikh1 and Matthew Grant2*
Abstract 
Background: Mycobacterium goodii is an infrequent human pathogen which has been implicated in prosthesis 
related infections and penetrating injuries. It is often initially misidentified as a gram-positive rod by clinical microbio-
logic laboratories and should be considered in the differential diagnosis.
Case presentation: We describe here the second reported case of M. goodii endocarditis. Species level identification 
was performed by 16S rDNA (ribosomal deoxyribonucleic acid) gene sequencing. The patient was successfully treated 
with mitral valve replacement and a prolonged combination of ciprofloxacin and trimethoprim/sulfamethoxazole.
Conclusion: Confirmation of the diagnosis utilizing molecular techniques and drug susceptibility testing allowed for 
successful treatment of this prosthetic infection.
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Background
Mycobacterium goodii is a rapidly growing non-tubercu-
lous mycobacterium (NTM) belonging to the Mycobac-
terium smegmatis [1] group. Its importance has become 
increasingly appreciated as a pathogen over the last 
20 years, with a predilection towards infecting tissues at 
the site of penetrating injuries. Antibacterial treatment 
strategies against this pathogen are diverse but reported 
case cure rates are high. Here we describe what the 
authors believe to be the second reported case of M. goo-
dii endocarditis ever reported (first time involving a ring 
annuloplasty).
Case presentation
A 67-year-old Caucasian man, retired financier, with a 
history of severe mitral regurgitation status post ring 
annuloplasty repair complicated by right sided hemo-
thorax requiring two reoperations to achieve hemostasis, 
presented to an outside hospital 3 weeks postoperatively 
with fever, loss of appetite, and gait disturbance.
On examination the patient vital signs were nor-
mal, lungs were clear, a mild 1/6 systolic murmur was 
appreciated at the apex, and a drain was in place for a 
groin seroma related to recent left heart catheterization. 
He had an unsteady gait and exhibited mild left lower 
extremity weakness (4/5). His brain magnetic resonance 
imaging showed multiple ring-enhancing lesions in the 
pons and posterior fossa suggestive of septic emboli. 
Transthoracic echocardiography showed moderate 
mitral regurgitation without any vegetation. Blood cul-
tures grew gram-positive rods suspicious for Actinomyces 
spp. and he was started on vancomycin and ampicillin/
sulbactam. He developed a morbilliform cutaneous erup-
tion felt to be related to the ampicillin and was switched 
to vancomycin/ceftriaxone. A computed tomography 
scan of the chest (Fig. 1) was done which showed bilateral 
infiltrates and mild pleural effusions.
The patient was then transferred to our hospital on 
day 14 for further management. A transesophageal 
echocardiogram (TEE) (Fig.  2) showed vegetations on 
the P3 annulus and evidence of ring dehiscence in A2, 
A3, and P3 areas. He completed penicillin desensitiza-
tion and was successfully narrowed to penicillin G to 
be optimally treated for presumptive actinomycotic 
endocarditis and both vancomycin and ceftriaxone were 
stopped. On hospital day 18 he underwent mitral valve 
replacement with a bioprosthetic valve (27 mm. St. Jude 
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prosthesis). Intraoperatively, vegetations were confirmed 
on the mitral valve and tissue cultures from the explanted 
native mitral valve suggested a rapid growing mycobacte-
rium rather than an Actinomyces spp. Empiric treatment 
with meropenem (1 g IV thrice a day)/amikacin (1 g IV 
per day)/clarithromycin (500  mg oral twice a day)/cip-
rofloxacin (400  mg IV twice a day) was initiated pend-
ing final confirmation and susceptibility testing. On day 
21 it was confirmed that the gram-positive isolate was a 
100% match to the M. goodii strain (American Type Cul-
ture Collection or ATCC #700504) using 16S sequencing 
(MicroSeq 500 bp 16S rDNA kit), but M. smegmatis could 
not be ruled out due to a high-level sequence homology 
[99.5% match to M. smegmatis type strain (ATCC 19420) 
with two mismatches]. Serial blood cultures sterilized on 
hospital day 26 and he was transferred to a nursing facil-
ity after repeat TEE showed a normally functioning pros-
thetic mitral valve.
On the day following discharge into the rehabilitation 
facility, the patient developed a maculopapular erup-
tion involving his flanks and back, which  progressed to 
involve his anterior trunk and all four limbs. He pre-
sented to the infectious diseases clinic 3 days after dis-
charge where the rash was suspected of being related to 
the meropenem and tigecycline was substituted; however, 
he had an acute anaphylactoid reaction (involving dysp-
nea and hypotension) during the loading dose of tige-
cycline (100 mg once) which was subsequently replaced 
with linezolid (600 mg oral twice a day). His susceptibility 
reports returned which showed the mycobacterium was 
susceptible to trimethoprim–sulfamethoxazole, amika-
cin, doxycycline, ciprofloxacin, imipenem, linezolid and 
resistant to clarithromycin. In accordance, his regimen 
was changed to ciprofloxacin (500 mg oral twice a day)/
trimethoprim–sulfamethoxazole (1 DS tablet oral twice a 
day).
The patient was ultimately treated with a total of 
6  months of therapy. He followed up in infectious dis-
eases clinic on days 61 and 135 and was contacted by 
phone 137 weeks post valve replacement and there were 
no complaints or signs of intervening relapse, was highly 
active and back to all his prior recreational activities.
Discussion
A broad literature search was done from PubMed, Sco-
pus and OvidSP databases containing the search terms 
M. goodii to try and identify all human infections with 
this organism. M. goodii was proposed as a new rapidly 
growing species related to M. smegmatis based on gene 
sequencing work by Brown et al. [1] in 1999 in continua-
tion to the work done by Wallace et al. [2]. We have sum-
marized to the best of our knowledge all the published 
reports about M. goodii infections (Table 1) after Brown 
[1]. A total of 45 cases (including our patient) have been 
reported to date. Eleven (25%) cases were wound/bone 
infections due to trauma. Twenty-two (49%) cases were 
iatrogenic, with eighteen (38%) involving infection of 
prosthetic materials. Eight (18%) cases were pulmonary, 
Fig. 1 Computed tomography of chest showing bilateral infiltrates 
and bilateral pleural effusion
Fig. 2 Trans-esophageal echocardiogram showing mitral valve 
vegetation in the mid-esophageal plane
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which were strongly associated with histological findings 
of lipoid or granulomatous pneumonias. Four (9%) cases 
had unclear clinical diagnosis but were confirmed to be 
M. goodii microbiologically.
Since there is no available clinical trial or prospective 
data to guide therapy for this infection, we extrapolated 
a treatment approach from the accumulated experience 
with other more common rapid growing NTM species 
to treat our patient with this incredibly rare disease. Our 
empiric regimen selection was further made challenging 
by the development of a second drug eruption and an 
anaphylactoid infusional reaction, both of which required 
cessation of drugs and subsequent drug substitution.
Conclusions
Rapid growing mycobacteria should be suspected in 
trauma or prosthetic related infections not responding to 
initial empiric therapies. Molecular techniques are rapid 
and reliable for confirmation of rapid growing myco-
bacterial infections and are recommended by the Infec-
tious Diseases Society of America guidelines [3]. Once 
rapid growing mycobacteria are suspected, 16S riboso-
mal sequencing should be used if available for species 
level identification. 16S rRNA gene sequences contain 
hypervariable regions that can provide species-specific 
signature sequences useful for identification of bacteria 
[4]. Since M. goodii has the ability to form biofilms [5], 
prosthesis removal is indicated to achieve cure if fea-
sible. Macrolides should not be included in the empiri-
cal/definitive treatment since it has been shown that the 
organism has intrinsic macrolide resistance conferred by 
novel rRNA methylase genes erm(38) and erm(39) [6, 7]. 
This has also been seen widely in the susceptibility test-
ing for the organism. The organism is usually susceptible 
to sulfonamides, amikacin, doxycycline, imipenem, fluo-
roquinolones and they should be optimized for dose and 
duration according to the severity and comorbidities.
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